Corbus Pharmaceuticals Holdings (CRBP) said Tuesday that CRB-701 has received fast track designation from the US Food and Drug Administration for the treatment of relapsed or refractory metastatic cervical cancer.
The company said the designation aims to facilitate the development and hasten the review of drugs that have the "potential to fill an unmet medical need."
Corbus said it recently completed enrollment of the dose escalation part of its phase 1 clinical trial of CRB-701 and expects to release the first data from the dose escalation clinical study in Q1.
Corbus shares were up 5.9% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments